A Randomized, Bilateral Comparison, Vehicle-Controlled, Safety and Tolerability Study of Topical PAT-001 for the Treatment of Congenital Ichthyosis
Phase of Trial: Phase II
Latest Information Update: 28 Dec 2017
At a glance
- Drugs Isotretinoin (Primary)
- Indications Congenital ichthyosiform erythroderma
- Focus Adverse reactions; Proof of concept
- Sponsors Patagonia Pharmaceuticals
- 20 Dec 2017 Status changed from recruiting to completed.
- 17 Jan 2017 Status changed from not yet recruiting to recruiting.
- 07 Nov 2016 According to an Almirall media release, this trial will initiate in Q1 2017.